Cara Therapeutics announced positive statistically significant results in a phase 2/3 trial for its drug I.V. CR845 which goal is to reduce pain caused by abdominal surgeries. Cara Therapeutics is a small-cap stock, so getting the drug approved will likely have a significant impact on the stock price.
This stock has amazing potential. I am surprised no one here is talking about it. I am in at $5 and quadrupled already....6,000 shared.
CARA is moving through the approval process for a pain medication that has been found to also stop itch for Kidney Dialysis patients equals + HUGE market...well into the billions. Zero competition. First in class. The pain medication is an opioid that DOES NOT cause addictive euphoria. Think...breakthrough of the century there....While the pain indication may be coming, it has had some problems in early studies. However, Pruritis Studies are crushing it. I encourage people to research it...its is undervalued at this point...you will thank me later.
If you are wondering where and who..is behind the company....YALE scientists....Stamford CT. Some industrial buying is starting. Black Rock owns over 2 mm shares.
Was added to Small Cap 600 earlier this week, you'll notice subsequent huge volume on Tuesday. Applied for a Marketing Authorization Application in the EU, for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. They had positive results from 2 Phase III trials and another 32 clinical trials. Decision expected in Q2 2022. It sounds like the drug is good and they just need to make it officially marketable.
